- You are viewing a Navigating Care library resource.
- Go to Library
Treatment of Refractory Gastrointestinal Stromal Tumors
For information about the treatments listed below, see the Treatment Option Overview section.
Many GISTs treated with a tyrosine kinase inhibitor (TKI) become refractory (stop responding) to the drug after a while. Treatment is usually a clinical trial with a different TKI or a clinical trial of a new drug.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
October 1, 2024.
Learn more:
- General Information About Gastrointestinal Stromal Tumors
- Stages of Gastrointestinal Stromal Tumors
- Treatment Option Overview
- Treatment of Resectable Gastrointestinal Stromal Tumors
- Treatment of Unresectable Gastrointestinal Stromal Tumors
- Treatment of Metastatic and Recurrent Gastrointestinal Stromal Tumors
- Treatment of Refractory Gastrointestinal Stromal Tumors
- To Learn More About Gastrointestinal Stromal Tumors
Related Articles
- General Information About Gastrointestinal Stromal Tumors
- Stages of Gastrointestinal Stromal Tumors
- Treatment Option Overview
- Treatment of Resectable Gastrointestinal Stromal Tumors
- Treatment of Unresectable Gastrointestinal Stromal Tumors
- Treatment of Metastatic and Recurrent Gastrointestinal Stromal Tumors
- Treatment of Refractory Gastrointestinal Stromal Tumors
- To Learn More About Gastrointestinal Stromal Tumors
More Resources
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
